期刊
MOLECULAR ONCOLOGY
卷 12, 期 4, 页码 561-576出版社
WILEY
DOI: 10.1002/1878-0261.12185
关键词
combination therapy; endocrine therapy; maintenance therapy; olaparib; PARP inhibition; prostate cancer
类别
资金
- Austrian Cancer Aid Society/Tyrol
- Austrian Science Fund (FWF) [P26799, P29457]
- Czech Ministry of Health (AZV) [15-28628A]
- Czech Ministry of Education (NPS I) [L01304]
- Czech Ministry of Education [7AMB16AT022]
- Austrian Science Fund (FWF) [P29457, P26799] Funding Source: Austrian Science Fund (FWF)
A number of prostate cancer (PCa)-specific genomic aberrations (denominated BRCAness genes) have been discovered implicating sensitivity to PARP inhibition within the concept of synthetic lethality. Recent clinical studies show favorable results for the PARP inhibitor olaparib used as single agent for treatment of metastatic castration-resistant PCa. Using 2D and 3D cell culture models mimicking the different treatment and progression stages of PCa, we evaluated a potential use for olaparib in combination with first-line endocrine treatments, androgen deprivation, and complete androgen blockade, and as a maintenance therapy following on from endocrine therapy. We demonstrate that the LNCaP cell line, possessing multiple aberrations in BRCAness genes, is sensitive to olaparib. Additive effects of olaparib combined with endocrine treatments in LNCaP are noted. In contrast, we find that the TMPRSS2:ERG fusion-positive cell lines VCaP and DuCaP do not show signs of synthetic lethality, but are sensitive to cytotoxic effects caused by olaparib. In consequence, additive effects of olaparib with endocrine therapy were not observable in these cell lines, showing the need for synthetic lethality in combination treatment regimens. Additionally, we show that PCa cells remain sensitive to olaparib treatment after initial androgen deprivation implicating a possible use of olaparib as maintenance therapy. In sum, our preclinical data recommend olaparib as a synthetic lethal treatment option in combination or sequenced to first-line endocrine therapy for PCa patients with diagnosed BRCAness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据